All In Biotech

Drug Trial Radar · NCT07214064

Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation

Safety and Feasibility of a Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation in AML, MDS/AML and Higher Risk MDS

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

27

Planned (sponsor's estimate)

Start

Feb 19, 2026

Primary completion

Aug 2027

Study completion Dec 2027

Sponsor

Lead sponsor
University Hospital TuebingenAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Safety and Feasibility of a Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation in AML, MDS/AML and Higher Risk MDS

Conditions

  • AML (Acute Myeloid Leukemia)
  • MDS/AML
  • MDS (Myelodysplastic Syndrome)

Interventions

  • RIC regimenDrug

    Venetoclax (Venclyxto®): 400 mg abs./d day -8 to -2, Fludarabine 30 mg/m2 BSA day -6 to day -2, Treosulfan 10 g/m2 BSA day -4 to day -2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment-Related Mortality (TRM) at day 28 after alloHCTTime frame: at day 28 after alloHCT

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Hospital , Department of Internal Medicine II

    Tübingen, Baden-Wurttemberg, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.